Abstract 196P
Background
We sought to explore whether the circulating proliferative T lymphocyte subtypes in patients with advanced gastric cancer (AGC) can be used as an indicator of prognosis.
Methods
Blood samples were collected from patients with AGC before treatment and analyzed by fluorescence-activated cell sorting analysis. Patients were divided into two groups based on the ratio of CD8+ T cells to CD4+ T cells and the ratio of CD8+ T cells to CD4+ T cells within Ki-67+ T cells. Survival between the groups was compared using the Kaplan-Meier method and the log-rank test. Multivariate analyses were also performed.
Results
A total of 92 patients enrolled in the study. The median age was 64.2 years, and the male-to-female ratio was 2.3:1. The median survival duration was 12.5 months. No significant differences in progression-free survival (PFS) and overall survival (OS) were observed between the groups with high and low CD8/CD4 ratios. However, the group with a high ratio of CD8/CD4 within proliferating T cells (n = 46) had a significantly longer OS (16.8 months vs. 11.3 months; p = 0.011) compared to the group with a low ratio of CD8/CD4 within proliferating T cells (n = 46). PFS did not vary between these proliferating CD8/CD4 ratio groups. A multivariate analysis indicated that the ratio of proliferating CD8 to CD4 was an independent prognostic factor for OS.
Conclusions
A high CD8/CD4 ratio among proliferating T cells in circulation could be associated with a better prognosis in patients with AGC receiving first-line chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract